Cargando…

Enzyme Models—From Catalysis to Prodrugs

Enzymes are highly specific biological catalysts that accelerate the rate of chemical reactions within the cell. Our knowledge of how enzymes work remains incomplete. Computational methodologies such as molecular mechanics (MM) and quantum mechanical (QM) methods play an important role in elucidatin...

Descripción completa

Detalles Bibliográficos
Autores principales: Breijyeh, Zeinab, Karaman, Rafik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198240/
https://www.ncbi.nlm.nih.gov/pubmed/34071328
http://dx.doi.org/10.3390/molecules26113248
_version_ 1783707090843336704
author Breijyeh, Zeinab
Karaman, Rafik
author_facet Breijyeh, Zeinab
Karaman, Rafik
author_sort Breijyeh, Zeinab
collection PubMed
description Enzymes are highly specific biological catalysts that accelerate the rate of chemical reactions within the cell. Our knowledge of how enzymes work remains incomplete. Computational methodologies such as molecular mechanics (MM) and quantum mechanical (QM) methods play an important role in elucidating the detailed mechanisms of enzymatic reactions where experimental research measurements are not possible. Theories invoked by a variety of scientists indicate that enzymes work as structural scaffolds that serve to bring together and orient the reactants so that the reaction can proceed with minimum energy. Enzyme models can be utilized for mimicking enzyme catalysis and the development of novel prodrugs. Prodrugs are used to enhance the pharmacokinetics of drugs; classical prodrug approaches focus on alternating the physicochemical properties, while chemical modern approaches are based on the knowledge gained from the chemistry of enzyme models and correlations between experimental and calculated rate values of intramolecular processes (enzyme models). A large number of prodrugs have been designed and developed to improve the effectiveness and pharmacokinetics of commonly used drugs, such as anti-Parkinson (dopamine), antiviral (acyclovir), antimalarial (atovaquone), anticancer (azanucleosides), antifibrinolytic (tranexamic acid), antihyperlipidemia (statins), vasoconstrictors (phenylephrine), antihypertension (atenolol), antibacterial agents (amoxicillin, cephalexin, and cefuroxime axetil), paracetamol, and guaifenesin. This article describes the works done on enzyme models and the computational methods used to understand enzyme catalysis and to help in the development of efficient prodrugs.
format Online
Article
Text
id pubmed-8198240
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81982402021-06-14 Enzyme Models—From Catalysis to Prodrugs Breijyeh, Zeinab Karaman, Rafik Molecules Review Enzymes are highly specific biological catalysts that accelerate the rate of chemical reactions within the cell. Our knowledge of how enzymes work remains incomplete. Computational methodologies such as molecular mechanics (MM) and quantum mechanical (QM) methods play an important role in elucidating the detailed mechanisms of enzymatic reactions where experimental research measurements are not possible. Theories invoked by a variety of scientists indicate that enzymes work as structural scaffolds that serve to bring together and orient the reactants so that the reaction can proceed with minimum energy. Enzyme models can be utilized for mimicking enzyme catalysis and the development of novel prodrugs. Prodrugs are used to enhance the pharmacokinetics of drugs; classical prodrug approaches focus on alternating the physicochemical properties, while chemical modern approaches are based on the knowledge gained from the chemistry of enzyme models and correlations between experimental and calculated rate values of intramolecular processes (enzyme models). A large number of prodrugs have been designed and developed to improve the effectiveness and pharmacokinetics of commonly used drugs, such as anti-Parkinson (dopamine), antiviral (acyclovir), antimalarial (atovaquone), anticancer (azanucleosides), antifibrinolytic (tranexamic acid), antihyperlipidemia (statins), vasoconstrictors (phenylephrine), antihypertension (atenolol), antibacterial agents (amoxicillin, cephalexin, and cefuroxime axetil), paracetamol, and guaifenesin. This article describes the works done on enzyme models and the computational methods used to understand enzyme catalysis and to help in the development of efficient prodrugs. MDPI 2021-05-28 /pmc/articles/PMC8198240/ /pubmed/34071328 http://dx.doi.org/10.3390/molecules26113248 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Breijyeh, Zeinab
Karaman, Rafik
Enzyme Models—From Catalysis to Prodrugs
title Enzyme Models—From Catalysis to Prodrugs
title_full Enzyme Models—From Catalysis to Prodrugs
title_fullStr Enzyme Models—From Catalysis to Prodrugs
title_full_unstemmed Enzyme Models—From Catalysis to Prodrugs
title_short Enzyme Models—From Catalysis to Prodrugs
title_sort enzyme models—from catalysis to prodrugs
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198240/
https://www.ncbi.nlm.nih.gov/pubmed/34071328
http://dx.doi.org/10.3390/molecules26113248
work_keys_str_mv AT breijyehzeinab enzymemodelsfromcatalysistoprodrugs
AT karamanrafik enzymemodelsfromcatalysistoprodrugs